Nitinotes Surgical Secures $9.3 Million in Funding for Revolutionary Robotic Suturing System

Nitinotes Surgical, a cutting-edge medical device company based in Caesarea, Israel, has successfully raised an impressive $9.3 million in funding to further its mission of revolutionizing endoscopic gastroplasty. This significant capital injection will be pivotal in enhancing the development and scalability of Nitinotes’ flagship product, the EndoZip™, an innovative endoscopic robotic suturing system. The EndoZip™ stands out for its ability to simplify and expedite the suturing process, making endoscopic gastroplasty a more accessible and efficient procedure. With clinical backing from prominent key opinion leaders (KOLs), the EndoZip™ addresses an urgent need in the medical community for a minimally invasive solution tailored for the over 700 million patients diagnosed with obesity class I and II, particularly those for whom conventional bariatric surgery is not a viable option. The funds raised will be channeled into further research and development, regulatory processes, and expanding Nitinotes' market presence. As the company gears up to enhance its technological capabilities, it remains committed to driving improved patient outcomes and accessibility in obesity treatment, ultimately changing the landscape of bariatric care. This funding announcement marks a significant milestone for Nitinotes Surgical as it embarks on this transformative journey, with the potential to impact countless lives through a safer and simpler approach to endoscopic procedures.